SG11201407163XA - Anti-egfr antibodies and uses thereof - Google Patents
Anti-egfr antibodies and uses thereofInfo
- Publication number
- SG11201407163XA SG11201407163XA SG11201407163XA SG11201407163XA SG11201407163XA SG 11201407163X A SG11201407163X A SG 11201407163XA SG 11201407163X A SG11201407163X A SG 11201407163XA SG 11201407163X A SG11201407163X A SG 11201407163XA SG 11201407163X A SG11201407163X A SG 11201407163XA
- Authority
- SG
- Singapore
- Prior art keywords
- egfr antibodies
- egfr
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261663984P | 2012-06-25 | 2012-06-25 | |
US201361821000P | 2013-05-08 | 2013-05-08 | |
PCT/US2013/047476 WO2014004427A2 (en) | 2012-06-25 | 2013-06-25 | Anti-egfr antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407163XA true SG11201407163XA (en) | 2014-11-27 |
Family
ID=48782632
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201610590UA SG10201610590UA (en) | 2012-06-25 | 2013-06-25 | Anti-egfr antibodies and uses thereof |
SG11201407163XA SG11201407163XA (en) | 2012-06-25 | 2013-06-25 | Anti-egfr antibodies and uses thereof |
SG10201804151QA SG10201804151QA (en) | 2012-06-25 | 2013-06-25 | Anti-egfr antibodies and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201610590UA SG10201610590UA (en) | 2012-06-25 | 2013-06-25 | Anti-egfr antibodies and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201804151QA SG10201804151QA (en) | 2012-06-25 | 2013-06-25 | Anti-egfr antibodies and uses thereof |
Country Status (24)
Country | Link |
---|---|
US (3) | US9132192B2 (en) |
EP (1) | EP2864357B1 (en) |
JP (1) | JP6486268B2 (en) |
KR (1) | KR20150023387A (en) |
CN (1) | CN104411722B (en) |
AR (1) | AR091545A1 (en) |
AU (2) | AU2013280610B2 (en) |
BR (1) | BR112014029099A2 (en) |
CA (1) | CA2876697C (en) |
CL (1) | CL2014003465A1 (en) |
CO (1) | CO7160093A2 (en) |
EA (1) | EA030421B1 (en) |
ES (1) | ES2816645T3 (en) |
HK (1) | HK1206040A1 (en) |
IL (1) | IL235392B (en) |
MX (1) | MX356329B (en) |
MY (2) | MY181086A (en) |
NZ (1) | NZ701633A (en) |
PH (1) | PH12014502437B1 (en) |
SG (3) | SG10201610590UA (en) |
TW (2) | TWI641619B (en) |
UY (1) | UY34876A (en) |
WO (1) | WO2014004427A2 (en) |
ZA (1) | ZA201407927B (en) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8791244B2 (en) | 2011-09-30 | 2014-07-29 | Regeneron Pharmaceuticals, Inc. | Anti-ErbB3 antibodies and uses thereof |
US9273143B2 (en) * | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
US9840560B2 (en) * | 2013-03-15 | 2017-12-12 | Alper Biotech Llc | Monoclonal antibodies to EGFR, and uses therefor |
US10844127B2 (en) | 2014-02-28 | 2020-11-24 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
SG10201805288QA (en) * | 2014-05-16 | 2018-07-30 | Ablynx Nv | Improved immunoglobulin variable domains |
ES2815572T3 (en) | 2014-05-16 | 2021-03-30 | Ablynx Nv | Immunoglobulin variable domains |
TW202340452A (en) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | Taurine supplemented cell culture medium and methods of use |
CN105017424B (en) * | 2015-08-31 | 2021-02-09 | 北京泱深生物信息技术有限公司 | EGFR antibody variable region and application thereof |
LT3365373T (en) | 2015-10-23 | 2021-05-25 | Merus N.V. | Binding molecules that inhibit cancer growth |
CN108602890A (en) | 2015-12-11 | 2018-09-28 | 瑞泽恩制药公司 | Method for reducing or preventing the tumour growth resistant to EGFR and/or ERBB3 retarding agents |
EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
WO2018182422A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
US20190010531A1 (en) | 2017-07-06 | 2019-01-10 | Regeneron Pharmaceuticals, Inc. | Cell culture process for making a glycoprotein |
TW201910354A (en) * | 2017-08-09 | 2019-03-16 | 荷蘭商美勒斯公司 | Antibodies that bind to epidermal growth factor receptor (EGFR) and cMET |
WO2019114793A1 (en) * | 2017-12-13 | 2019-06-20 | 凯惠科技发展(上海)有限公司 | Egfr antibody, preparation method therefor and application thereof |
SG11202004380QA (en) | 2017-12-22 | 2020-06-29 | Regeneron Pharma | System and method for characterizing drug product impurities |
KR20200115485A (en) | 2018-01-31 | 2020-10-07 | 리제너론 파마슈티칼스 인코포레이티드 | Systems and methods for characterizing drug product impurities |
TWI786265B (en) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | System and method for characterizing protein dimerization |
BR112020013426A2 (en) | 2018-02-28 | 2020-12-01 | Regeneron Pharmaceuticals, Inc. | methods for identifying a virus in a sample and for detecting viral nucleic acids in a cell culture sample |
BR112020018235A2 (en) * | 2018-03-14 | 2020-12-29 | F. Hoffmann-La Roche Ag | METHODS FOR GENERATING A POLYNUCLEOTIDE LIBRARY, POLYNUCLEOTIDE LIBRARIES, USE OF A LIBRARY, METHOD FOR GENERATING AN ANTIBODY LIBRARY AND METHOD OF SELECTING AN ANTIBODY |
IL307577A (en) | 2018-03-19 | 2023-12-01 | Regeneron Pharma | Microchip capillary electrophoresis assays and reagents |
TW202016125A (en) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | Systems and methods for quantifying and modifying protein viscosity |
CN108680746A (en) * | 2018-06-05 | 2018-10-19 | 中国科学院合肥物质科学研究院 | It is a kind of control lung carcinoma cell vigor molecular target and its application |
CN112218877A (en) | 2018-08-27 | 2021-01-12 | 瑞泽恩制药公司 | Application of Raman spectroscopy in downstream purification |
JP2021535361A (en) | 2018-08-30 | 2021-12-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Methods for characterizing protein complexes |
AU2020208396A1 (en) | 2019-01-16 | 2021-05-20 | Regeneron Pharmaceuticals, Inc. | Methods for identifying free thiols in proteins |
EP3941941A1 (en) | 2019-03-22 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Egfr x cd28 multispecific antibodies |
SG11202110911RA (en) | 2019-05-13 | 2021-10-28 | Regeneron Pharma | Improved competitive ligand binding assays |
EP4005593A4 (en) * | 2019-07-24 | 2023-08-16 | Sinocelltech Ltd. | Multivariable dosing method for use in treating high-egfr expression cancer |
CA3216345A1 (en) | 2019-09-24 | 2021-04-01 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
AU2020394428A1 (en) | 2019-11-25 | 2022-07-14 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
IL294765B2 (en) | 2020-01-21 | 2023-12-01 | Regeneron Pharma | Deglycosylation methods for electrophoresis of glycosylated proteins |
DK3872091T3 (en) | 2020-02-26 | 2023-09-11 | Vir Biotechnology Inc | ANTIBODIES AGAINST SARS-COV-2 |
KR20230058094A (en) | 2020-08-31 | 2023-05-02 | 리제너론 파아마슈티컬스, 인크. | Asparagine supply strategies to improve cell culture performance and mitigate asparagine sequence variants |
AU2021385363A1 (en) | 2020-11-25 | 2023-06-08 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
IL303675A (en) | 2020-12-17 | 2023-08-01 | Regeneron Pharma | Fabrication of protein-encapsulating microgels |
EP4281542A1 (en) | 2021-01-20 | 2023-11-29 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
TW202246325A (en) | 2021-03-03 | 2022-12-01 | 美商再生元醫藥公司 | Systems and methods for quantifying and modifying protein viscosity |
US20220309215A1 (en) | 2021-03-26 | 2022-09-29 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
EP4337676A1 (en) | 2021-05-10 | 2024-03-20 | Entrada Therapeutics, Inc. | Antigen-binding and antigen degradation constructs |
EP4348234A1 (en) | 2021-06-01 | 2024-04-10 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
WO2023039457A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins |
CA3232463A1 (en) | 2021-09-20 | 2023-03-23 | Philip Mellors | Methods of controlling antibody heterogeneity |
CA3230984A1 (en) | 2021-10-07 | 2023-04-13 | Ross BROWNE | Systems and methods of ph modeling and control |
AU2022359898A1 (en) | 2021-10-07 | 2024-03-21 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
TW202330104A (en) | 2021-10-26 | 2023-08-01 | 美商再生元醫藥公司 | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
CN116333119B (en) * | 2021-12-16 | 2024-02-23 | 徕特康(苏州)生物制药有限公司 | anti-EGF receptor antibody, preparation method and application thereof |
TW202346856A (en) | 2022-03-18 | 2023-12-01 | 美商里珍納龍藥品有限公司 | Methods and systems for analyzing polypeptide variants |
US20240027432A1 (en) | 2022-07-13 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Mild acid immunoassays for detection of analytes |
WO2024076926A1 (en) | 2022-10-03 | 2024-04-11 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies |
CN117430707B (en) * | 2023-10-25 | 2024-04-19 | 重庆天科雅生物科技有限公司 | Preparation method of CIK cells and application of CIK cells in treatment of cancers |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE122004000008I1 (en) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanized heregulin antibody. |
RU2170257C2 (en) | 1994-03-17 | 2001-07-10 | Мерк Патент Гмбх | Anti-egfr single-chain fv, chimeric anti-egfr antibody and method of its preparing, pharmaceutical composition for treatment of patients with tumors, agent for diagnosis of localization and estimation of tumor growth |
US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
AU2002257132A1 (en) * | 2001-04-06 | 2002-10-21 | The Trustees Of The University Of Pennsylvania | Erbb interface peptidomimetics and methods of use thereof |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
IL159225A0 (en) | 2001-06-13 | 2004-06-01 | Genmab As | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
WO2003012072A2 (en) * | 2001-08-03 | 2003-02-13 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
RU2338751C2 (en) * | 2002-07-15 | 2008-11-20 | Дженентек, Инк. | MEANS OF IDENTIFICATION OF TUMOURS, ACQUISITIVE TO TREATMENT BY ANTIBODIES AGAINST ErbB2 |
US8323987B2 (en) * | 2004-02-17 | 2012-12-04 | The University Of North Carolina At Chapel Hill | Modulation of epidermal growth factor heterodimer activity |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
AU2006301426A1 (en) * | 2005-10-11 | 2007-04-19 | Ablynx N.V. | NanobodiesTM and polypeptides against EGFR and IGF-IR |
PT1951759E (en) | 2005-11-12 | 2010-04-01 | Lilly Co Eli | Anti-egfr antibodies |
US7498142B2 (en) | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
MX2008014804A (en) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor. |
RU2448979C2 (en) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Human antibodies to delta-like human ligand-4 |
EP2644204B1 (en) * | 2008-03-18 | 2017-04-19 | Genentech, Inc. | Combinations of an Anti-HER2 antibody-drug conjugate and pertuzumab |
TWI496582B (en) * | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | Bispecific egfr/igfir binding molecules |
TWI461211B (en) * | 2009-03-20 | 2014-11-21 | Genentech Inc | Anti-her antibodies |
JP5612663B2 (en) * | 2009-04-07 | 2014-10-22 | ロシュ グリクアート アクチェンゲゼルシャフト | Bispecific anti-ErbB-1 / anti-c-Met antibody |
JO3182B1 (en) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | High Affinity Human Antibodies to Human Angiopoietin-2 |
WO2011156617A2 (en) * | 2010-06-09 | 2011-12-15 | Aveo Pharmaceuticals, Inc. | Anti-egfr antibodies |
-
2013
- 2013-06-20 TW TW102121841A patent/TWI641619B/en not_active IP Right Cessation
- 2013-06-20 TW TW107129255A patent/TW201843172A/en unknown
- 2013-06-25 CA CA2876697A patent/CA2876697C/en active Active
- 2013-06-25 CN CN201380033859.6A patent/CN104411722B/en not_active Expired - Fee Related
- 2013-06-25 MY MYPI2017704291A patent/MY181086A/en unknown
- 2013-06-25 AU AU2013280610A patent/AU2013280610B2/en active Active
- 2013-06-25 MX MX2014014361A patent/MX356329B/en active IP Right Grant
- 2013-06-25 WO PCT/US2013/047476 patent/WO2014004427A2/en active Application Filing
- 2013-06-25 AR ARP130102231 patent/AR091545A1/en unknown
- 2013-06-25 MY MYPI2014003097A patent/MY164604A/en unknown
- 2013-06-25 NZ NZ701633A patent/NZ701633A/en not_active IP Right Cessation
- 2013-06-25 ES ES13735519T patent/ES2816645T3/en active Active
- 2013-06-25 EA EA201590085A patent/EA030421B1/en not_active IP Right Cessation
- 2013-06-25 KR KR20147035064A patent/KR20150023387A/en not_active Application Discontinuation
- 2013-06-25 EP EP13735519.4A patent/EP2864357B1/en active Active
- 2013-06-25 BR BR112014029099A patent/BR112014029099A2/en not_active Application Discontinuation
- 2013-06-25 SG SG10201610590UA patent/SG10201610590UA/en unknown
- 2013-06-25 JP JP2015518639A patent/JP6486268B2/en active Active
- 2013-06-25 SG SG11201407163XA patent/SG11201407163XA/en unknown
- 2013-06-25 UY UY34876A patent/UY34876A/en unknown
- 2013-06-25 SG SG10201804151QA patent/SG10201804151QA/en unknown
- 2013-06-25 US US13/925,923 patent/US9132192B2/en active Active
-
2014
- 2014-10-29 IL IL235392A patent/IL235392B/en active IP Right Grant
- 2014-10-30 PH PH12014502437A patent/PH12014502437B1/en unknown
- 2014-10-30 ZA ZA2014/07927A patent/ZA201407927B/en unknown
- 2014-12-19 CL CL2014003465A patent/CL2014003465A1/en unknown
- 2014-12-24 CO CO14283133A patent/CO7160093A2/en unknown
-
2015
- 2015-07-13 HK HK15106655.6A patent/HK1206040A1/en unknown
- 2015-08-06 US US14/820,324 patent/US9789184B2/en active Active
-
2017
- 2017-09-11 US US15/700,665 patent/US20180036405A1/en not_active Abandoned
-
2018
- 2018-07-05 AU AU2018204895A patent/AU2018204895A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL281250A (en) | Anti-phf-tau antibodies and their uses | |
ZA201407927B (en) | Anti-egfr antibodies and uses thereof | |
HK1207092A1 (en) | Anti-hla-b27 antibodies and uses thereof -hla-b27 | |
HRP20190358T1 (en) | Anti-asic1 antibodies and uses thereof | |
ZA201500457B (en) | Anti-kit antibodies and uses thereof | |
ZA201501858B (en) | Anti-mcam antibodies and associated methods of use | |
EP2822592A4 (en) | Tgf- 1 specific antibodies and methods and uses thereof | |
EP2756094A4 (en) | Anti-b7-h4 antibodies and their uses | |
HK1205523A1 (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof ---1(big-et-1) | |
HUE037613T2 (en) | Anti-tlr4 antibodies and uses thereof | |
EP2830660A4 (en) | Anti-sema4d antibodies and epitopes | |
EP2900693A4 (en) | Adcc-mediating antibodies, combinations and uses thereof | |
GB201208372D0 (en) | Antibodies and uses thereof |